BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 32869174)

  • 1. Alvimopan: A cost-effective tool to decrease cystectomy length of stay.
    Manger JP; Nelson M; Blanchard S; Helo S; Conaway M; Krupski TL
    Cent European J Urol; 2014; 67(4):335-41. PubMed ID: 25667750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxegol versus Alvimopan for Enhancing Postoperative Recovery following Radical Cystectomy for Bladder Cancer.
    Kirk PS; Wang A; Raskolnikov D; Psutka SP; Gore JL; Nyame YA; Kelly J; Wright JL
    Urol Pract; 2022 Sep; 9(5):364-370. PubMed ID: 37145718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alvimopan Use, Outcomes, and Costs: In reply to Fujita.
    Ehlers AP; Flum DR; Farjah F
    J Am Coll Surg; 2016 Aug; 223(2):423-4. PubMed ID: 27456253
    [No Abstract]   [Full Text] [Related]  

  • 4. Influencing Factors of Preference Signaling in the 2022 Urology Residency Match.
    Kim JK; Morrison B; Bylund J; Rasper A; Dropkin BM
    Urology; 2023 May; 175():35-41. PubMed ID: 36805414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Peripherally Acting μ-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review.
    Rekatsina M; Paladini A; Drewes AM; Ayob F; Viswanath O; Urits I; Corli O; Pergolizzi J; Varrassi G
    Cureus; 2021 Jul; 13(7):e16201. PubMed ID: 34367804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alvimopan for recovery of bowel function after radical cystectomy].
    Kranz J; Krabbe LM
    Urologe A; 2018 Feb; 57(2):207-210. PubMed ID: 29396627
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of alvimopan use in benign urinary tract reconstruction.
    Hensley P; Higgins M; Rasper A; Ziada A; Strup S; Coleman C; Ruf K; Gupta S
    Int Urol Nephrol; 2021 Jan; 53(1):77-82. PubMed ID: 32869174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alvimopan provides rapid gastrointestinal recovery without nasogastric tube decompression after radical cystectomy and urinary diversion.
    Vora AA; Harbin A; Rayson R; Christiansen K; Ghasemian R; Hwang J; Verghese M
    Can J Urol; 2012 Jun; 19(3):6293-8. PubMed ID: 22704317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional outcomes and cost effectiveness of using alvimopan to lower gastrointestinal morbidity after cystectomy and urinary diversion.
    Vora A; Marchalik D; Nissim H; Kowalczyk K; Bandi G; McGeagh K; Lynch J; Venkatesan K; Ghasemian R; Hwang J; Hwang MV
    Can J Urol; 2014 Apr; 21(2):7222-7. PubMed ID: 24775576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alvimopan for recovery of bowel function after radical cystectomy.
    Sultan S; Coles B; Dahm P
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012111. PubMed ID: 28462518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.
    Lee CT; Chang SS; Kamat AM; Amiel G; Beard TL; Fergany A; Karnes RJ; Kurz A; Menon V; Sexton WJ; Slaton JW; Svatek RS; Wilson SS; Techner L; Bihrle R; Steinberg GD; Koch M
    Eur Urol; 2014 Aug; 66(2):265-72. PubMed ID: 24630419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alvimopan use in laparoscopic and open bowel resections: clinical results in a large community hospital system.
    Absher RK; Gerkin TM; Banares LW
    Ann Pharmacother; 2010 Nov; 44(11):1701-8. PubMed ID: 20858770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystectomy for benign disease: readmission, morbidity, and complications.
    Erpelding SG; Dugan A; Isharwal S; Strup S; James A; Gupta S
    Can J Urol; 2018 Oct; 25(5):9473-9479. PubMed ID: 30281004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan.
    Hirobe M; Tanaka T; Shindo T; Ichihara K; Hotta H; Takahashi A; Kato R; Yanase M; Matsukawa M; Itoh N; Kunishima Y; Taguchi K; Horita H; Masumori N
    Int J Clin Oncol; 2018 Aug; 23(4):734-741. PubMed ID: 29442282
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.